Germany: Thermo Fisher’s acquisition of Qiagen falls through

Thermo Fisher Scientific’s US$11.5bn acquisition of German genetic testing company Qiagen has fallen through after the minimum acceptance threshold condition to the offer was not satisfied. Only 47% of shares were tendered by Qiagen shareholders, which falls short of the 66% required. “We respect the decision of our shareholders and will now continue to execute…

You must be a HMI Subscriber to view this content.

Subscribe Now »